Migraine Breakthrough: Not So Fast

Migraine Breakthrough: Not So Fast

Source: 
Forbes
snippet: 
Two weeks ago the Food and Drug Administration (FDA) approved the monoclonal antibody erenumab (brand name Aimovig, marketed by Amgen and Novartis) for the prevention of migraine in adult patients.